These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21603831)

  • 61. Renal protection by N-acetylcysteine.
    Shehabi Y
    Br J Anaesth; 2007 Feb; 98(2):270; author reply 270-1. PubMed ID: 17251216
    [No Abstract]   [Full Text] [Related]  

  • 62. Porphyria cutanea tarda as a cause of bullous dermatosis of hemodialysis. A case report and review of the literature.
    Hanno R; Callen JP
    Cutis; 1981 Sep; 28(3):261-3. PubMed ID: 7028406
    [No Abstract]   [Full Text] [Related]  

  • 63. Diagnosis of common dermopathies in dialysis patients: a review and update.
    Markova A; Lester J; Wang J; Robinson-Bostom L
    Semin Dial; 2012 Jul; 25(4):408-18. PubMed ID: 22809004
    [TBL] [Abstract][Full Text] [Related]  

  • 64. N-acetylcysteine reduces malondialdehyde levels in chronic hemodialysis patients--a pilot study.
    Trimarchi H; Mongitore MR; Baglioni P; Forrester M; Freixas EA; Schropp M; Pereyra H; Alonso M
    Clin Nephrol; 2003 Jun; 59(6):441-6. PubMed ID: 12834176
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Delayed onset of overt porphyria cutanea tarda in a patient on long-term haemodialysis. A case report.
    King J; Day RS; Milne FJ; Bezwoda WR; Viljoen JD; Kramer S
    S Afr Med J; 1983 May; 63(19):743-6. PubMed ID: 6845091
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Porphyria cutanea tarda in a hemodialysis patient.
    Huang YC; Wang CC; Sue YM
    QJM; 2013 Jun; 106(6):591-2. PubMed ID: 22753666
    [No Abstract]   [Full Text] [Related]  

  • 67. Pseudoporphyria or porphyria cutanea tarda? Diagnostic and treatment difficulties.
    Fevang SA; Kroon S; Skadberg Ø
    Acta Derm Venereol; 2008; 88(4):426-7. PubMed ID: 18709330
    [No Abstract]   [Full Text] [Related]  

  • 68. [Detection of pseudo-porphyria cutanea tarda in 100 hemodialyzed patients (author's transl)].
    Griffon-Euvrard S; Thivolet J; Laurent G; Calemard E; Gaillemin J; Perrot H; Ortonne JP
    Dermatologica; 1977; 155(4):193-9. PubMed ID: 902828
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bullous amyloidosis in a hemodialysis patient is myeloma-associated rather than hemodialysis-associated amyloidosis.
    Chang SL; Lai PC; Cheng CJ; Yang LC; Hong HS
    Amyloid; 2007 Jun; 14(2):153-6. PubMed ID: 17577689
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Porphyria cutanea tarda in the setting of renal failure. Response to renal transplantation.
    Stevens BR; Fleischer AB; Piering F; Crosby DL
    Arch Dermatol; 1993 Mar; 129(3):337-9. PubMed ID: 8095384
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hyperpigmentation, bullae, and keratotic papules in a renal dialysis patient. Pseudoporphyria cutanea tarda (PPCT), acquired perforating disorder of renal dialysis (APD).
    Ross M; White GM
    Arch Dermatol; 1993 Feb; 129(2):231, 234. PubMed ID: 8094609
    [No Abstract]   [Full Text] [Related]  

  • 72. [Dermatosis bullosa in patient with chronic renal failure under hemodialysis treatment--case report].
    Wanic-Kossowska M; Furmanowska A; Pawliczak E; Kozioł L; Bajew L; Kobelski M; Czekalski S
    Pol Arch Med Wewn; 2002 Jul; 108(1):671-4. PubMed ID: 12412412
    [TBL] [Abstract][Full Text] [Related]  

  • 73. N-Acetylcysteine in the prevention of ototoxicity.
    Tepel M
    Kidney Int; 2007 Aug; 72(3):231-2. PubMed ID: 17653228
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Management of porphyria cutanea tarda in the setting of chronic renal failure: a case report and review.
    Shieh S; Cohen JL; Lim HW
    J Am Acad Dermatol; 2000 Apr; 42(4):645-52. PubMed ID: 10727312
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pseudoporphyria induced by voriconazole.
    Sharp MT; Horn TD
    J Am Acad Dermatol; 2005 Aug; 53(2):341-5. PubMed ID: 16021136
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pseudoporphyria associated with hemodialysis.
    Felix RH; Silva MF; Almeida JB; Neto PB
    Kidney Int; 2011 Jan; 79(1):140. PubMed ID: 21157468
    [No Abstract]   [Full Text] [Related]  

  • 77. Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients.
    Thaha M; Widodo ; Pranawa W; Yogiantoro M; Tomino Y
    Clin Nephrol; 2008 Jan; 69(1):24-32. PubMed ID: 18226399
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Clinical review of pseudoporphyria].
    Velander MJ; Þorsteinsdóttir S; Bygum A
    Ugeskr Laeger; 2015 Feb; 177(6):. PubMed ID: 25650579
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial.
    Reinecke H; Fobker M; Wellmann J; Becke B; Fleiter J; Heitmeyer C; Breithardt G; Hense HW; Schaefer RM
    Clin Res Cardiol; 2007 Mar; 96(3):130-9. PubMed ID: 17180572
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Acetylcysteine for radiocontrast nephropathy.
    Tepel M; Zidek W
    Curr Opin Crit Care; 2001 Dec; 7(6):390-2. PubMed ID: 11805540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.